Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Statkevich

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|May 16, 2019
Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying ClearanceLora Hamuro, Paul Statkevich, Akintunde Bello, et al.
Current Medical Research and Opinion|September 24, 2004
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteersLarisa Reyderman, Teddy Kosoglou, Tanya Boutros, et al.
Current Medical Research and Opinion|August 9, 2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibeLarisa Reyderman, Teddy Kosoglou, David L Cutler, et al.
Clinical Pharmacokinetics|August 10, 2002
Lack of clinically relevant interaction between desloratadine and erythromycinChristopher Banfield, Thomas Hunt, Larisa Reyderman, et al.
Cancer|July 19, 2002
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulationRonald M Bukowski, Craig Tendler, David Cutler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumorsNeal E Ready, Alan Lipton, Yali Zhu, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid TumorsKinjal Sanghavi, Jason Zhang, Xiaochen Zhao, et al.
Clinical Pharmacokinetics|May 6, 2005
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactionsTeddy Kosoglou, Paul Statkevich, Amy O Johnson-Levonas, et al.
Clinical Pharmacology in Drug Development|April 14, 2017
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy VolunteersMatt S Anderson, Teddy Kosoglou, Paul Statkevich, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|May 16, 2019
Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying ClearanceLora Hamuro, Paul Statkevich, Akintunde Bello, et al.
Current Medical Research and Opinion|September 24, 2004
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteersLarisa Reyderman, Teddy Kosoglou, Tanya Boutros, et al.
Current Medical Research and Opinion|August 9, 2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibeLarisa Reyderman, Teddy Kosoglou, David L Cutler, et al.
Clinical Pharmacokinetics|August 10, 2002
Lack of clinically relevant interaction between desloratadine and erythromycinChristopher Banfield, Thomas Hunt, Larisa Reyderman, et al.
Cancer|July 19, 2002
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulationRonald M Bukowski, Craig Tendler, David Cutler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumorsNeal E Ready, Alan Lipton, Yali Zhu, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 12, 2019
Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid TumorsKinjal Sanghavi, Jason Zhang, Xiaochen Zhao, et al.
Clinical Pharmacokinetics|May 6, 2005
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactionsTeddy Kosoglou, Paul Statkevich, Amy O Johnson-Levonas, et al.
Clinical Pharmacology in Drug Development|April 14, 2017
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy VolunteersMatt S Anderson, Teddy Kosoglou, Paul Statkevich, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.
Pageof 5